Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface
Myasthenia Gravis
Explore 22 assets in Myasthenia Gravis →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06220201CT.gov A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myasthenia Gravis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface (this asset) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | P1 | CC · 43 |
| Camustine | Fred Hutchinson Cancer Center | P2 | CCC |
| Prednisone | Fred Hutchinson Cancer Center | P2 | CCC |
| Etoposide | Fred Hutchinson Cancer Center | P2 | CCC |
| Melphalan | Fred Hutchinson Cancer Center | P2 | CCC |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2 | CCC |
| Cytarabine | Fred Hutchinson Cancer Center | P2 | CCC |
| Cyclophosphamide | Kite, A Gilead Company | P1 | CCC |
| Fludarabine | Kite, A Gilead Company | P1 | CCC |
+14 more in the Myasthenia Gravis cohort
Other indications for Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Aggressive B-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 47 |
| Diffuse Large B-Cell Lymphoma | — | P1 | CC · 47 |
| Non-Hodgkin Lymphoma | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bms-986353 Is An Investigational Cd19-Targeted Car T-Cell Product. The Cd19-Specific Car Consists Of A Single-Chain Variable Fragment (Scfv) Binding Domain Derived From A Cd19-Specific Monoclonal Antibody (Mab; Fmc63), An Igg-Derived Hinge Region, A Cd28 Transmembrane Domain, And The Cd137 (41Bb) And Cd3? Chain Signaling Domains. The Third-Generation Sin Lentiviral Vector, Which Encodes The Car Domains Described Above, Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Expressed Separately From The Cd19 Car On The T Cell Surface in Myasthenia Gravis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bms-986353-is-an-investigational-cd19-targeted-car-t-cell-product-the-cd19-specific-car-consists-of-a-single-chain-variable-fragment-scfv-binding-domain-derived-from-a-cd19-specific-monoclonal-antibody-mab-fmc63-an-igg-derived-hinge-region-a-cd28-transmembrane-domain-and-the-cd137-41bb-and-cd3-chain-signaling-domains-the-third-generation-sin-lentiviral-vector-which-encodes-the-car-domains-described-above-also-encodes-a-truncated-human-epidermal-growth-factor-receptor-egfrt-that-is-expressed-separately-from-the-cd19-car-on-the-t-cell-surface-myasthenia-gravis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →